MGP Ingredients remains a Buy as its valuation is very attractive and management has reaffirmed its 2026 guidance despite facing operational pressures. The company shows early signs of recovery with new branded spirits like 'MGP Chapter One' and growth in its Penelope and Ingredient Solutions segments. While inventory buildup and rising long-term debt require monitoring, liquidity is comfortable and management is actively controlling costs. Trading near 52-week lows and at deep discounts to peers, even modest business improvements could lead to significant stock gains.
MGP Ingredients is the focus of this update, with Pluang providing a snapshot of the Consumer Staples sector as of Oct 02, 2026 04:11 WIB. Among 51 priced US stocks in this sector on Pluang, 18 rose and 33 fell today. Notable movements include National Beverage Corp. (FIZZ) at USD 29.74 with a 1-day change of +1.85% and a typical hold time of 31 days, MONDELEZ INTERNATIONAL INC (MDLZ) at USD 57.85 down 1.62% with a typical hold time of 107 days and order activity skewed 70% Sell / 30% Buy, and Honest Company Inc (HNST) at USD 5.05 down 1.56% with a typical hold time of 39 days and 100% Buy order activity.
Wells Fargo initiated coverage on BlackRock with an 'Overweight' rating, highlighting it as a good entry point for investors. Analysts expect BlackRock's Q3 earnings per share to rise to $14.25 from $11.55 a year ago, with revenue projected at $7.56 ...
Nike reported earnings per share of $0.48, beating estimates, but revenue fell short at $11.21 billion due to weak demand in Greater China and rising competition. The company issued a cautious fiscal 2027 outlook with EPS forecast between $1.15 and $...
NETSOL Technologies reported a record $20.7 million revenue in fiscal 2026 Q4, with net income rising 45.9% to $3.8 million. The company improved its gross margin to 63.6% and operating margin to 21.6%, reflecting enhanced profitability. For fiscal 2...
On October 1, 2026, Nexalin Technology surged 76.4% after securing a 10-year exclusive deal for its medical device in South America. Armada Acquisition Corp. II jumped 42.9% following shareholder approval of its merger with Evernorth, expected to clo...
Jefferies analyst Roger Song set a $150 price target for Nektar Therapeutics, suggesting a 219% upside from its $46.99 trading price. This comes after Nektar presented positive six-month Phase IIb trial results for its alopecia drug REZPEG, which als...
